- For QA teams: the development puts batch impact assessment and investigation quality in focus.
- For QC laboratories: it highlights the range of analytical and microbiological tests that determine continued specification compliance.
- For Manufacturing: it reinforces that quality failures can still emerge after release through regulatory surveillance.
Sterility, Dissolution and Assay Failures Drive CDSCO’s 40-Batch NSQ Alert
The July alert covers a broad mix of products, including injectables, antibiotics, analgesics, cardiovascular and anti-diabetic medicines, gastrointestinal products, vitamins, cough and cold formulations, and surgical products.
Several cases show why the findings matter beyond a single dosage form. Sodium Chloride Injection IP 0.9% manufactured by MKA Remedies failed particulate contamination testing. Metronidazole Infusion BP 0.5% from Althea Pharma failed sterility testing. Meanwhile, Paracetamol Tablets IP 500 mg from Cotec Healthcare failed dissolution testing.
Other products failed different quality parameters. Oxytocin Injection IP 5 IU/ml from Jackson Laboratories did not conform for HPLC identification and particulate matter. Bupropion Hydrochloride prolonged-release tablets from Live Well Healthcare failed HPLC identification, IR identification and assay. Telmisartan Tablets IP 20 mg manufactured by Medicamen Biotech failed dissolution testing.
The list also includes Metformin Hydrochloride prolonged-release and Glimepiride tablets with a metformin dissolution failure. In addition, Ibuprofen Tablets IP 400 mg failed dissolution testing for ibuprofen.
| Quality signal | Examples reported in July | Main quality focus |
|---|---|---|
|
Sterility |
Metronidazole Infusion; Compound Sodium Lactate Injection |
Sterility assurance |
|
Particulate matter |
Sodium Chloride, Oxytocin and Amikacin injections |
Injectable quality |
|
Dissolution |
Paracetamol, Telmisartan, Metformin combination, Ibuprofen |
Product performance |
|
Identification / assay |
Bupropion, Racecadotril and combination products |
Analytical control |
The CDSCO alert therefore does not point to one repeated test failure. Instead, it shows multiple types of non-conformance across different products and manufacturers.
Under Section 16(1)(a) of India’s Drugs and Cosmetics Act, 1940, drugs must comply with applicable standards. The source report states that failure to meet those standards can lead to regulatory action, including recalls, investigations and legal proceedings where warranted.
40 Failed Batches: The QA and QC Checks Worth Reassessing Now
Quality teams can use the CDSCO NSQ drug alert as a trigger to compare these failure modes with their own internal trends. QA and QC should confirm that OOS and post-market quality signals follow approved investigation procedures. Teams should review recurring dissolution, assay, sterility and particulate trends, verify traceability across batch records and laboratory results, and ensure significant recurring issues enter CAPA and quality-review processes where appropriate.
If an NSQ result appeared in one of your released batches, which would trigger faster cross-functional escalation at your site: a sterility or particulate failure, or a dissolution or assay failure?
CDSCO’s NSQ Alert Is Out, Which Regulatory Actions Could Follow?
The next developments to monitor are any CDSCO or state-level follow-up actions involving the listed batches. These could include investigations, recalls or other regulatory measures where authorities consider them warranted. Quality teams should also monitor later NSQ alerts for repeated products, manufacturers or failure patterns.
Turning NSQ Signals Into Stronger CAPA and Quality Control
For teams managing recurring deviations, OOS investigations, CAPA effectiveness, or batch-record controls, Zamann Pharma’s Quality Management System support offers practical help across critical quality processes. The service covers areas such as batch record review, deviation and CAPA management, internal audits, and ongoing QMS improvement.
Source: Medicaldialogues.In